Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. Biopharmaceutical company Chimerix Inc....
Streetwise Reports | April 29, 2020 |

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...
Streetwise Reports | September 26, 2019 |

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. This morning Durham, N.C.-based Dova Pharmaceuticals Inc. (DOVA:NASDAQ) announced ...
Streetwise Reports | October 1, 2019 |

A billion-ton copper opportunity in Zambia

The following is a transcription of the above video, and The Market Online has edited it for clarity . Midnight Sun Mining Corp. (TSXV:MMA) is an exploration company focused on its flagship Solwezi Project in the heart of the Zambia-Congo Copper Belt. Here to ...
Ryan Dhillon | March 26, 2024 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

Emergency Technical Traders Market Crash Update & Video Analysis

The US stock market opened Sunday, March 8, 2020, dramatically lower. Oil collapsed 25% to near $30. Gold shot higher to levels just above $1700. All of the major US indexes were lower than 5%. As of this morning, the US major indexes are lower by 6.40%, and oil down 23%. Bo...
Chris Vermeulen | March 9, 2020 |

Can the S&P 500 Bulls Sound the All Clear Now?

The buyers repelled the opening selling pressure, and gradually made their way higher. While it wasn’t smooth sailing throughout the whole session, they overcame every attempt of the sellers. Closing near the daily highs, and with futures little changed during ...
Monica Kingsley | April 9, 2020 |

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ) , which focuse...
Streetwise Reports | May 6, 2020 |

Atomera: When Will Revenues Start?

Atomera Inc. (ATOM:NASDAQ) reported earnings on Wednesday after the close. The numbers are rather meaningless for Atomera as they are pre-revenue. What investors are looking for is clues to when revenues will start and the likelihood that customers will adopt Atomera's...
Streetwise Reports | August 14, 2019 |
1 2